A study of Abalone Haemocyanin for cold sores
A Randomised, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate Safety and Efficacy of Topical Abalone Haemocyanin Once Daily for the Treatment of Herpes Labialis in Immunocompetent Patients
Marine Biotechnology Australia Pty Limited
210 participants
Aug 25, 2011
Interventional
Conditions
Summary
Herpes labialis (cold sores) caused by herpes simplex virus type 1 (HSV-1) is a common condition affecting millions of people worldwide. The pathogenesis of the disease suggests that brief and early immunogenic therapy may be a logical approach. Abalone Haemocyanin (AH) derived from live abalone. The literature and clinical data generated by the sponsor of this study, indicate that AH has the potential for prophylaxis and therapeutic treatment of all stages of oral herpes. The proposed study is to look at the safety and effectiveness of topical AH for 5 days compared with placebo.
Eligibility
Inclusion Criteria1
- Male or female with history of recurrent cold sores and have experienced at least three episodes in the previous 12 months.
Exclusion Criteria1
- Any significant unstable medical condition, allergic reaction or sensitivity to haemocyanin from any source, or a food allergy to seafood or shellfish.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Abalone Haemocyanin (AH) 50mg applied topically once daily for 5 days within 6 hours of profromal symptom.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000920998